Business
Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting
MORRISVILLE, N.C., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for
About this update from Liquidia Corporation
[{"type":"text","content":"MORRISVILLE, N.C., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today the company will present two oral presentations at the CHEST 2025 annual meeting on October 19-22, 2025, in Chicago. The company’s two presentations will focus on new data from its ASCENT trial pertaining to both the safety and exploratory efficacy of LIQ861 DPI treprostinil in PH-ILD patients through Week 16, and observed changes in the cardiac effort of PH-ILD patients.Oral Presentations include:Rapid Fire Oral Presentation, Tuesday, October 21, 2025, 10:20 a.m. – 10:24 a.m. CTTitle: Changes in Cardiac Effort in Pulmonary Hypertension-Interstitial Lung Disease: Insights from ASCENTPresenter: Dr. Dan Lachant - University of Rochester Medical CenterSession: On the Hunt for New Approaches to Diagnose and Monitor PHLate-Breaking Rapid Fire Oral Presentation, Tuesday, October 21, 2025, 1:52 p.m. – 1:57 p.m. CTTitle: Safety and Exploratory Efficacy Data of LIQ861 DPI Treprostinil in PH-ILD: ASCENT to Week 16Presenter: Dr. Nicholas Kolaitis - University of California, San Francisco (UCSF) Medical Center Session: Pulmonary Fibrosis: Advances in Pharmacotherapy Late-Breaking Scientific AbstractsUpon presentation, the slides will be available on the Publications page of Liquidia’s website located at https://liquidia.com/products-and-pipeline/publications.About ASCENT An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH (ASCENT), listed as ClinicalTrials.gov ID NCT06129240, will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 and 3 pulmonary hypertension. Cohort A includes 54 subjects who have WHO Group 3 Pulmonary Hypertension associated with interstitial lung disease (PH-ILD). Additional cohorts from either Group 1 or Group 3 may be defined in future protocol amendments. Scheduled study visits to the clinic will occur at Screening, Baseline, Week 8, Week 16, Week 24, and Week 52. During this time, dose titration may be ordered at the Investigator's discretion and in accordance with the guidance provided. The primary objective of this study is to evaluate the safety and tolerability of LIQ861 in subjects with WHO Group 1 & 3 P...